Jihyun Lee ^1* Eliane Duperrex ¹ Ibrahim El-Battrawy ^2,3,4,5 Alyssa Hohn ^3* Ardan M. Saguner ^6,7 Firat Duru ^6,7 Vishalini Emmenegger ¹ Lukas Cyganek ^8,9 Andreas R. Hierlemann ^1* Hasan Ulusan ^1*

• ¹ ETH Zürich, Zurich, Switzerland
• ² St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany
• ³ Partner Site Heidelberg/Mannheim, German Centre for Cardiovascular Research (DZHK), Heidelberg, Baden-Württemberg, Germany
• ⁴ Institute of Physiology, Ruhr-University Bochum, Bochum, Germany
• ⁵ Department of Molecular and Experimental Cardiology, Ruhr-University Bochum, Bochum, Germany
• ⁶ University Heart Center Zürich, Zurich, Zürich, Switzerland
• ⁷ Center for Translational and Experimental Cardiology, University Hospital Zürich, Zürich, Zürich, Switzerland
• ⁸ Partner site Göttingen, German Center for Cardiovascular Research, Göttingen, Lower Saxony, Germany
• ⁹ University Medical Center Göttingen, Göttingen, Lower Saxony, Germany

In recent years, high-density microelectrode arrays (HD-MEAs) have emerged as a valuable tool in preclinical research for characterizing the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). HD-MEAs enable the capturing of both extracellular and intracellular signals on a large scale, while minimizing potential damage to the cell. However, despite the technological advancements of HD-MEAs, there is a lack of effective data-analysis platforms that are capable of processing and analyzing the data, particularly in the context of cardiac arrhythmias and drug testing.To address this need, we introduce CardioMEA, a comprehensive data-analysis platform designed specifically for HD-MEA data that have been obtained from iPSC-CMs.CardioMEA features scalable data processing pipelines and an interactive web-based dashboard for advanced visualization and analysis. In addition to its core functionalities, CardioMEA incorporates modules designed to discern crucial electrophysiological features between diseased and healthy iPSC-CMs. Notably, CardioMEA has the unique capability to analyze both extracellular and intracellular signals, thereby facilitating customized analyses for specific research tasks. We demonstrate the practical application of CardioMEA by analyzing electrophysiological signals from iPSC-CM cultures exposed to seven antiarrhythmic drugs. CardioMEA holds great potential as an intuitive, user-friendly platform for studying cardiac diseases and assessing drug effects.